Skip to main content
Clinical Trials/JPRN-UMIN000014894
JPRN-UMIN000014894
Completed
Phase 2

Randomized phase II trial of chemoradiotherapy with S-1 versus gemcitabine and S-1 combination therapy as neoadjuvant treatment in patients with resecatble pancreatic cancer - Randomized phase II trial of chemoradiotherapy with S-1 versus gemcitabine and S-1 combination therapy as neoadjuvant treatment in patients with resecatble pancreatic cancer (JASPAC 04)

Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)0 sites103 target enrollmentAugust 19, 2014

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
resectable pancreatic cancer
Sponsor
Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)
Enrollment
103
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 19, 2014
End Date
April 30, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1 Treatment history with gemcitabine or fuluoruracil, 2 Use of flucytosine, phenytoin, and warfarin potassium, 3 Fibroid lung or interstitial pneumonia, 4 Pleural lung or ascites 5 Watery diarrhea, etc

Outcomes

Primary Outcomes

Not specified

Similar Trials